Greenwich LifeSciences Inc.
| NYSE: GLSI | Healthcare / Biotechnology / USA |
| 13.79 | +0.1100 | +0.80% | Vol 53.63K | 1Y Perf -30.28% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 13.56 | ASK | 14.30 | ||
| Open | 14.02 | Previous Close | 13.79 | ||
| Pre-Market | - | After-Market | 13.57 | ||
| - - | -0.22 -1.60% |
| Target Price | 78.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 465.63 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 45.57 | Earnings Rating | — | |
| Market Cap | 177.17M | Earnings Date | 3rd Apr 2023 | |
| Alpha | 0.20 | Standard Deviation | 1.31 | |
| Beta | 5.66 |
Today's Price Range 13.5614.30 | 52W Range 6.8222.11 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.39% | ||
| 1 Month | -12.22% | ||
| 3 Months | -9.28% | ||
| 6 Months | 51.54% | ||
| 1 Year | -30.28% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -33.71 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -33.19 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -34.29 | |||
Return on invested Capital Q | -14.72 | |||
Return on invested Capital Y | -16.88 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -25.90 | ||||
| 12.32 | ||||
| - | ||||
| - | ||||
| -47.10 | ||||
| -0.48 | ||||
| 12.33 | ||||
| 1.20 | ||||
| 174.26M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 65.70 | ||||
| 65.70 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.19 | -0.18 | 5.26 |
| Q02 2022 | -0.19 | -0.06 | 68.42 |
| Q01 2022 | -0.19 | -0.15 | 21.05 |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 3rd Apr 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 53.63K |
| Shares Outstanding | 12.85K |
| Shares Float | 3.12M |
| Trades Count | 835 |
| Dollar Volume | 748.78K |
| Avg. Volume | 36.41K |
| Avg. Weekly Volume | 34.15K |
| Avg. Monthly Volume | 37.81K |
| Avg. Quarterly Volume | 37.27K |
Greenwich LifeSciences Inc. (NYSE: GLSI) stock closed at 13.79 per share at the end of the most recent trading day (a 0.8% change compared to the prior day closing price) with a volume of 53.63K shares and market capitalization of 177.17M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Greenwich LifeSciences Inc. CEO is Snehal Patel.
The one-year performance of Greenwich LifeSciences Inc. stock is -30.28%, while year-to-date (YTD) performance is -9.28%. GLSI stock has a five-year performance of %. Its 52-week range is between 6.8241 and 22.11, which gives GLSI stock a 52-week price range ratio of 45.57%
Greenwich LifeSciences Inc. currently has a PE ratio of -25.90, a price-to-book (PB) ratio of 12.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.19%, a ROC of -34.29% and a ROE of -33.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Greenwich LifeSciences Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Greenwich LifeSciences Inc.’s next earnings report date is 03rd Apr 2023.
The consensus rating of Wall Street analysts for Greenwich LifeSciences Inc. is Strong Buy (1), with a target price of $78, which is +465.63% compared to the current price. The earnings rating for Greenwich LifeSciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Greenwich LifeSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Greenwich LifeSciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.28, ATR14 : 1.09, CCI20 : 79.88, Chaikin Money Flow : 0.11, MACD : -0.49, Money Flow Index : 61.83, ROC : 6.73, RSI : 48.02, STOCH (14,3) : 70.39, STOCH RSI : 0.80, UO : 50.96, Williams %R : -29.61), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Greenwich LifeSciences Inc. in the last 12-months were: Frank Joseph Daugherty (Buy at a value of $16 250), Jaye Thompson (Buy at a value of $36 261), Snehal Patel (Buy at a value of $1 148 301)
Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients.
CEO: Snehal Patel
Telephone: +1 832 819-3232
Address: 3992 Bluebonnet Drive, Stafford 77477, TX, US
Number of employees: 3
